ClinicalTrials.gg
CompletedNCT03988309Updated May 31, 2025

STRATA: Safe Testing of Risk for AsymptomaTic MicrohematuriA

An interventional study of Cxbladder in Hematuria and Urothelial Carcinoma, sponsored by Pacific Edge Limited. Completed at 12 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-31.

Sponsored by Pacific Edge Limited · Not applicable, Interventional, and Diagnostic

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
554
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies in Hematuria with a site in United States — 5 open to participants now, 6 under way, 2 of them phase 3. Hematuria · United States.

Enrollment
5th of 13
554 · median 138
Started
2019
with 2 others
No phase
6 of 20
2 open now
Registered
11th of 20
by date
Lead sponsor
2 of 20
Pacific Edge Limited

Among the 20 studies in Hematuria with a site in United States, this one is the 5th largest by enrollment of the 13 interventional ones that give a count, is one of 3 that started in 2019, is one of 6 with no phase, and was the 11th registered.

Hematuria

67 studies on the registry are indexed under Hematuria; 16 are open to participants now.

Browse Hematuria studies →

Open to participants now

5 of the 20 studies in Hematuria with a site in United States are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 10 Hematuria studies recruiting now, 7 (70%) set no upper age limit and 1 (10%) stops at 75 or younger; 2 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Hematuria with a site in United States, or all of them as a file.
02

Study summary

To evaluate the clinical utility associated with the integration of Cxbladder into the evaluation of subjects presenting with hematuria for evaluation of urothelial carcinoma (UC) without compromising detection of UC.

Read the detailed description

Randomised two arm pragmatic clinical study to be conducted at multiple sites in US and Canada. The trial will recruit hematuria subjects, presenting to qualified sites (academic, community), who are being evaluated for urothelial carcinoma (UC). Up to 100 consecutive eligible subjects will be recruited per site.

03

Conditions studied

  • Hematuria
  • Urothelial Carcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient is undergoing investigation of recent confirmed hematuria, as defined by the AUA/SUFU Guideline (Barocas DA, Boorjian SA, Alvarez RD et al. Microhematuria: AUA/SUFU guideline, J Urol 2020; 204:778) (by either flexible or rigid cystoscopy/TURBT), including hematuria subjects referred due to suspicious/positive imaging, in order to determine the presence of urothelial carcinoma.
  • Able to provide a voided urine sample of the required minimum volume
  • Able to give written consent
  • Able and willing to comply with study requirements
  • Aged 18 years or older

Exclusion criteria

Exclusion Criteria

  • Prior history of bladder or pelvic radiotherapy. Prior history prostate or renal cell carcinoma within the last 5 years.
  • Prior genitourinary manipulation (flexible or rigid cystoscopy / catheterisation, urethral dilation) in the 14 days before urine collection,
  • Known current pregnancy
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
554 participants (actual)

Study arms

  • Active comparator
    Test, subjects categorised as "low risk" or "Not low risk"

    A clinical risk factor nomogram risk classification will be used in this study. The nomogram categorizes subjects as either "low risk" or "not low risk" categories. "Low risk" subjects satisfy all conditions and "not low risk" satisfies at least one of the conditions.The Cxbladder Triage test result will be provided to physicians for all "low risk" subjects on the test arm. If a "low risk" subject has a Cxbladder Triage negative test result then the indication is to rule out the subject without further assessment. The decision to rule-out or further evaluate is solely that of the physician and subject. If the "low risk" subjects are not Cxbladder Triage negative then a Cxbladder Detect test result will also be provided. The indication is further evaluation as per standard of care. Subjects categorised as "not low risk" will be evaluated as per standard of care. Note that Cxbladder test results will be available for eventual analysis for these subjects.

    Diagnostic Test: Cxbladder

  • No intervention
    Control

    Subjects on the control arm will be on standard of care. Trial nomogram clinical risk factor categorization for control arm subjects will not be provided to the physician (but appropriate information will be collected on the CRF to enable sub-group analysis) No Cxbladder test results will be provided for control arm subjects. Note that Cxbladder test results will be available for eventual analysis for these subjects.

Interventions

  • Diagnostic testCxbladder

    The Cxbladder Triage test result will be provided to physicians for all "low risk" subjects on the test arm. If a "low risk" subject has a Cxbladder Triage negative test result then the indication is to rule out the subject without further assessment. The decision to rule-out or further evaluate is solely that of the physician and subject. If the "low risk" subjects are not Cxbladder Triage negative then a Cxbladder Detect test result will also be provided. The indication is further evaluation as per standard of care. "Not low risk" patients will be evaluated as per standard of care.

06

What researchers measure

Primary outcomes

  1. To measure the change in cystoscopy procedure use count between control and test arms when Cxbladder Triage is used in the evaluation

    To evaluate the increase in utility as defined by the reduction in cystoscopy procedure count when Cxbladder is used in the evaluation. The comparison will be made when comparing test and control arms on a per subject basis. The gold standard for determination of a confirmed clinical diagnosis is cystoscopy confirmed by pathology, plus imaging or any follow-up investigations relating to the visit.

    Time frame: The outcome measure will be assessed by 6 months after trial completion.

Secondary outcomes

  1. To measure the change in total procedure use (and the invasive procedure sub-group) count between control and test arms when Cxbladder is used in the evaluation.

    To evaluate the increase in utility as defined by the reduction in total procedures (and the invasive procedures subgroup) count when Cxbladder is used in the evaluation. The comparison will be made when comparing test and control arms on a per subject basis.

    Time frame: The outcome measure will be assessed by 6 months after trial completion.

  2. To measure the number of subjects who were incorrectly diagnosed associated with the integration of Cxbladder into the evaluation of subjects (or sub-cohorts on test and control arms) presenting with hematuria for evaluation of UC

    To quantify the false negative rate (the percentage of the negative fraction incorrectly diagnosed) associated with the integration of Cxbladder into the evaluation of subjects (or sub-cohorts on test and control arms) presenting with hematuria for evaluation of UC

    Time frame: The outcome measure will be assessed by 6 months after trial completion.

  3. To clinically validate the performance characteristics and test negative rate of the Cxbladder Detect+ test.

    The Cxbladder Detect+ test results will be compared to that of cystoscopy, which is the gold standard method for diagnosing urothelial cancer; the true positive and true negative rates will be measured, along with the false positive and false negative rates of the test. The results will be reported as sensitivity, specificity, positive and negative predictive value and test negative rate of the Cxbladder Detect+ test for detecting urothelial cancer in patients referred for evaluation of hematuria.

    Time frame: The outcome measure will be assessed by 6 months after trial completion.

  4. Quantify performance characteristics of Cxbladder signatures including for the detection of high grade/stage UC.

    The Cxbladder signature test results will be compared to that of cystoscopy, which is the gold standard method for diagnosing urothelial cancer; the true positive and true negative rates will be measured, along with the false positive and false negative rates of the test. The results will be reported as sensitivity, specificity, positive and negative predictive value of the Cxbladder signature tests for detecting urothelial cancer in patients referred for evaluation of hematuria.

    Time frame: The outcome measure will be assessed by 6 months after trial completion.

07

Study locations

12 sites
  • Institute of Urology, USC Norris Comprehensive Cancer Center
    Los Angeles, California 90089, United States
  • Avant Concierge Urology
    Winter Garden, Florida 34787, United States
  • Accellacare
    Chicago, Illinois 60515, United States
  • Allina Health Cancer Institute
    Minneapolis, Minnesota 55407-3799, United States
  • University of Minnesota, Department of Urology
    Minneapolis, Minnesota 55455, United States
  • Division of urology, Penn State Milton S Hershey Medical Center
    Hershey, Pennsylvania 17033-0850, United States
  • Carolina Urologic Research Center
    Myrtle Beach, South Carolina 29572, United States
  • Department of Urology,Vanderbilt University
    Nashville, Tennessee 37232, United States
  • UT Southwestern Medical Center
    Dallas, Texas 75390, United States
  • UTHSA - Mays Cancer Center
    San Antonio, Texas 78229, United States
  • The prostate centre- Diamond Health care centre
    Vancouver, British Columbia V5Z1M9, Canada
  • London Health Sciences Centre Victoria Hospital
    London, Ontario N6A5W9, Canada
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2019 to primary completion in Jul 2024, 58 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 24, 2019
First posted
Jun 17, 2019
StartActual
Sep 11, 2019
Primary completionActual
Jul 24, 2024
CompletionActual
Jul 24, 2024
Last update
May 31, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 31, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03988309
Lead sponsor
Pacific Edge Limited
Responsible party
Sponsor
First posted
Jun 17, 2019
Start date
Sep 11, 2019
Primary completion
Jul 24, 2024
Completion
Jul 24, 2024
Last update
May 31, 2025

Study contacts

Tony Lough, PhD
study chair · Pacific Edge Pty Ltd

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion